On September 14, 2023, the Federal Trade Commission (FTC) issued a statement condemning pharmaceutical manufacturers ... or “Orange Book” as it is more commonly known.

Pharmaceutical manufacturers are required to list in the Orange Book for each product they manufacture any patents that the manufacturers claim would be infringed in the production of the drug by ...